1. Zynex will hold a Q1 conference call on April 29, 2025. 2. Financial results will be announced before the call. 3. The call will include a Q&A with management. 4. Zynex focuses on non-invasive medical devices for pain management. 5. Investor details are provided for participation in the call.
The upcoming financial results could indicate growth and investor interest. Historically, positive earnings calls have led to stock price increases.
The earnings announcement could significantly impact investor sentiment and share price, especially if results exceed expectations.
The impact will be felt soon after the earnings announcement on April 29. Immediate investor reactions usually follow such events.
ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025. Financial results will be issued in a press release prior to the call.
Zynex management will host the conference call, followed by a question and answer session.
Date: Tuesday, April 29, 2025
Time: 4:15 PM Eastern Time (2:15 PM Mountain Time)
U.S. & Canada dial-in number: 800-836-8184
International number: 646-357-8785
Webcast: 1Q25 Webcast Link
The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Brian M. Prenoveau, CFA
MZ Group – MZ North America
info@example.com
+561 489 5315
SOURCE Zynex, Inc.